ClinicalTrials.gg
RecruitingNCT06917573PALACEUpdated Nov 19, 2025

PALACE: Cemiplimab Trial According to ctDNA Levels

A Phase 2 interventional study of Cemiplimab and Carboplatin in Non Small Cell Lung Cancer Metastatic, Lung Diseases and Stage IV Non-small Cell Lung Cancer, sponsored by Fundación GECP. Recruiting at 20 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-19.

Primary conditionCarcinoma, Non-Small-Cell LungRegistry: Lung DiseasesReclassifiedWhy we changed it
Registry
Lung Diseases — the first condition term the registry derived for this study.
ClinicalTrials.gg
Carcinoma, Non-Small-Cell Lung
Why
  1. The study's listed conditions name Carcinoma, Non-Small-Cell Lung, a narrower term within Lung Diseases.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Fundación GECP · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
63
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 30 studies testing cemiplimab in Carcinoma, Non-Small-Cell Lung — 19 open to participants now, 23 under way, 4 of them phase 3. cemiplimab · Carcinoma, Non-Small-Cell Lung.

Planned enrollment
14th of 30
63 · median 62
Started
2025
with 9 others
Phase 2
19 of 30
13 open now
Primary completion
2031-12
later than 20 of 22 live
Registered
21st of 30
by date
Lead sponsor
1 of 30
Fundación GECP

Among the 30 studies testing cemiplimab in Carcinoma, Non-Small-Cell Lung, this one is the 14th largest by planned enrollment, is one of 10 that started in 2025, is one of 19 in phase 2, reaches primary completion later than 20 of the 22 other live ones, and was the 21st registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

19 of the 30 studies testing cemiplimab in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

13 more — sign in →

By country, each count listing its studies:

All 19 open studies →

About cemiplimab

cemiplimab: first FDA approval 2018 (LIBTAYO), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies testing cemiplimab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This is an open-label, non-randomised, phase II, multicenter clinical trial. 63 stage IV or stage IIIB/C not candidates for definitive chemo/radiotherapy or surgical resection non-small cell lung cancer (NSCLC) per the 8th edition TNM with no prior systemic anti-cancer therapy will be enrolled in this trial to determine whether therapy decision making based on ctDNA analysis improves overall survival.

Read the detailed description

This is an open-label, non-randomised, phase II, multicenter clinical trial. The total sample size is 63 patients. The population to be included are stage IV or stage IIIB/C not candidates for definitive chemo/radiotherapy or surgical resection non-small cell lung cancer (NSCLC) per the 8th edition TNM with no prior systemic anti-cancer therap.

Patients will be treated with Cemiplimab for 2 cycles and after response evaluation and ctDNA levels analysis, patients will be treated with Cemiplimab plus chemotherapy or cemiplimab monotherapy depending on response and ctDNA levels.

The primary research goal is to determine whether therapy decision making based on ctDNA analysis improves overall survival.

Patient accrual is expected to be completed within 1.5 years excluding a run-in-period of 4-6 months. An estimated treatment period of 2 years, 2 years of follow-up and the preparation of the final report and the close out visit are expected to extend the study duration to a total of 6.5 years.

03

Conditions studied

  • Non Small Cell Lung Cancer Metastatic
  • Lung Diseases
  • Stage IV Non-small Cell Lung Cancer
  • Stage III Non-small Cell Lung Cancer
  • Respiratory Tract Neoplasms
  • Thoracic Neoplasms

Keywords

  • Cemiplimab
  • ctDNA levels
  • Chemotherapy
  • Non-resectable non-small cell lung cancer
04

In context

Carcinoma, Non-Small-Cell Lung Reclassified

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

This study's planned enrollment of 63 is close to the median of 62 across 6,034 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.

Browse Carcinoma, Non-Small-Cell Lung studies →

Lead sponsor

Fundación GECP is the lead sponsor of 25 studies on the registry; 8 are open to participants now.

Compared within Carcinoma, Non-Small-Cell Lung, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lung Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed stage IV or stage IIIB/C not candidates for definitive chemo/radiotherapy or surgical resection non-small cell lung cancer (NSCLC) per the 8th edition TNM with no prior systemic anti-cancer therapy
  • PDL1 ≥50%
  • performance status 0-1
  • Patients aged ≥ 18 years
  • Prior or neoadjuvant chemotherapy for early stage is permitted if completed at least 6 months prior to enrolment
  • Presence of at least one by CT-scan per version 1.1
  • Anticipated >12 weeks
  • Correct hematological, hepatic and renal function
  • Patient consent must be obtained in the appropriate manner as established in the applicable local and regulatory requirements
  • Patients must be accessible for treatment and follow-up
  • Women of , including women who had their last menstrual period in the last 2 years, must have a negative serum or urine pregnancy test within 3 days before enrolment.
  • All sexually active men and women of childbearing potential must use a highly effective method during the study treatment and for a period of at least 4 months following the last administration of trial drugs

Exclusion criteria

Exclusion Criteria:

  • Patients whose tumors harbor an activating mutation in EGFR, ALK translocation, or ROS Proto-Oncogene 1 (ROS1) rearrangements sensitive to available targeted inhibitor therapy
  • Patients with grade ≥2 neuropathy
  • Pregnant or breastfeeding women
  • Patients with a weight loss >10% within the previous 3 months
  • Patients with carcinomatous meningitis
  • Patients with a history of other malignant diseases within the past 3 years
  • Patients must have recovered from a major surgery at least 14 days prior to enrolment
  • Patients with active or uncontrolled infections or with serious medical conditions or disorders that may not allow patient management as established in the protocol
  • Prior treatment with antineoplasic drugs or thoracic radiotherapy for any reason different from the ones specific in the inclusion criteria
  • Patients who have received prior , adjuvant chemotherapy, radiotherapy, or chemo-radiotherapy with curative intent for non- disease less than 6 months before enrollment since the last chemotherapy, radiotherapy, or chemo-radiotherapy
  • Patients with a combination of small cell lung cancer and non-small cell lung cancer, a carcinoid lung tumor or large cell neuroendocrine carcinoma
  • Has known allergy or to components of study drug
  • Significant comorbidities that preclude the administration of chemotherapy according to the investigator's criteria
  • Ongoing or recent evidence of significant disease that required treatment with systemic treatments
  • Untreated (es) that may be considered active
  • Immunosuppressive doses within 4 weeks prior to the first dose of cemiplimab
  • Uncontrolled infection with or or ; or diagnosis of immunodeficiency
  • History of interstitial lung disease or active, noninfectious pneumonitis that required immune-suppressive doses of glucocorticoids to assist with management.
  • History of documented allergic reactions or acute hypersensitivity reactions attributed to antibody treatments
  • Patients with a history of solid organ transplant
  • Receipt of within 30 days of first study treatment
  • Women of , or sexually active men, who are unwilling to practice highly effective prior to the initial dose/start of the first treatment prior to the start of the first treatment, during the study, and for at least 4 months after the last dose.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
63 participants (estimated)

Study arms

  • Experimental
    Experimental

    A. Cemiplimab monotherapy \- Cemiplimab Cemiplimab will be administered in monotherapy for 2 cycles. After 2 cycles of treatment and after response evaluation according to RECIST criteria and ctDNA quantification, patient will receive cemiplimab + chemotherapy or continue treatment with cemiplimab monotherapy Cemiplimab monotherapy will be administered until disease progression, unacceptable toxicity, loss of clinical benefit as judged by the investigator or up to a maximum of 2 years of treatment. B. Cemiplimab + chemotherapy The treatment with chemotherapy will be selected according to investigator's choice. Carboplatin and Pemetrexed or Carboplatin plus taxanes is recommended.

    Drug: Cemiplimab · Drug: Carboplatin · Drug: Paclitaxel

Interventions

  • Patients will receive Cemiplimab administered by IV infusion over 30 minutes every 28 days (Q3W) until disease progression, unacceptable toxicity, loss of clinical benefit as judged by the investigator or up to a maximum of 2 years of treatment. Structure: is a high affinity hinge-stabilized IgG4P human antibody to the PD-1receptor (PDCD1, CD279) that blocks PD 1/PD L1 mediated T cell inhibition. Binding of the PD-1 ligands PD-L1 and PD-L2, to the PD-1 receptor found on T cells, inhibits T-cell proliferation and cytokine production. Upregulation of PD-1 ligands occurs in some tumors and signaling through this pathway can contribute to inhibition of active T-cell immune surveillance of tumors. Route of administration: Intravenous infusion.

    Also known as: REGN2810

  • Patients will receive Carboplatin administered by IV infusion for 2 cycles. Structure: The cis-diamino (cyclobutane-1, 1 dicarboxylate) platin. Stability: 24 hours at ambient temperature in 5% glucose, glucosaline or physiologic saline. It is recommended not to dilute with chlorinated solutions since this could affect the carboplatin. Route of administration: Intravenous infusion.

    Also known as: Paraplatin, Carboplatine

  • Patients will receive Paclitaxel administered by IV infusion for 2 cycles. Structure: A diterpene whose composition is: 5b, 20- epoxy-1, 2a, 4,7b, 10b, 13a-hexahidroxytax-11-en 9 one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)- N-benzoyl-3-phenylisoserine. Stability: Concentrations of 0.3-1.2 mg/ml in 5% dextrose or normal saline have demonstrated chemical and physical stability for more than 27 hours at ambient temperature (25ºC approximately). The intact vial must be stored between 15º and 25ºC. Guidelines of Paclitaxel administration: Paclitaxel must be administered by infusion over 3 hours in dextrose (D5W) or normal saline (NS). The concentration must not exceed 1.2 mg/ml.

    Also known as: Taxol

07

What researchers measure

Primary outcomes

  1. To determine whether therapy decision making based on ctDNA analysis improves overall survival

    Test whether the addition of chemotherapy in patients receiving Cemiplimab, based on the ctDNA levels after two cycles of Cemiplimab, improves overall survival (OS) at 24 months. OS defined as the time from enrolment to death from any cause.

    Time frame: From the date of the end of two cycles of Cemiplimab treatment until 24 months

Secondary outcomes

  1. To assess the efficacy of the treatment in terms of the Progression Free Survival (PFS) at 12 months

    PFS defined as the time from enrollment to the first occurrence of disease progression or death from any cause as determined by the investigator according to RECIST v1.1

    Time frame: From the date of the end of treatment until 12 months

  2. To evaluate the sites of first failure

    To evaluate the sites of first relapse or progression

    Time frame: From the date of the end of treatment until the date of last follow up, assessed up to 24 months

  3. Duration of response (DOR)

    To evaluate the efficacy of cemiplimab as measured by investigator. Assessed as duration of response (DOR) according to RECIST v1.1

    Time frame: From date of documentation of tumor response until date of first documented progression, assessed up to 24 months

08

Study locations

19 of 20 sites recruiting
  • Hospital General de Alicante
    Alicante, Alicante 03010, Spain
    Recruiting
    • Bartomeu Massutí, MD · Contact
    • Bartomeu Massutí, MD · Principal investigator
  • Hospital General de Elche
    Elche, Alicante 03203, Spain
    Recruiting
    • Javier David Benitez Fuentes, MD · Contact
    • Javier David Benitez Fuentes, MD · Principal investigator
  • ICO Badalona, Hospital Germans Trias i Pujol
    Badalona, Barcelona 08916, Spain
    Recruiting
    • Marc Cucurull, MD · Contact
    • Marc Cucurull, MD · Principal investigator
  • Hospital Universitari Vall d' Hebron
    Barcelona, Barcelona 08035, Spain
    Recruiting
    • Patricia Iranzo, MD · Contact
    • Patricia Iranzo, MD · Principal investigator
  • Hospital de la Santa Creu i Sant Pau
    Barcelona, Barcelona 08041, Spain
    Recruiting
    • Sergio Martínez Recio, MD · Contact
    • Sergio Martínez Recio, MD · Principal investigator
  • ICO Hospitalet
    L'Hospitalet de Llobregat, Barcelona 08908, Spain
    Recruiting
    • Ernest Nadal, MD · Contact
    • Ernest Nadal, MD · Principal investigator
  • Hospital De Basurto
    Bilbao, Bilbao 48013, Spain
    Recruiting
    • Mª Angeles Sala González, MD · Contact
    • Mª Angeles Sala González, MD · Principal investigator
  • Hospital Universitario Jerez De La Frontera
    Jerez de la Frontera, Cádiz 11407, Spain
    Not yet recruiting
    • Mª Ángeles Moreno, MD · Contact
    • Mª Ángeles Moreno, MD · Principal investigator
  • Hospital Dr. Josep Trueta
    Girona, Girona 17007, Spain
    Recruiting
    • Joaquim Bosch, MD · Contact
    • Joaquim Bosch · Principal investigator
  • Hospitalario Universitario A Coruña
    A Coruña, La Coruña 15006, Spain
    Recruiting
    • Rosario García Campelo, MD · Contact
    • Rosario García Campelo, MD · Principal investigator
  • Hospital Universitario Dr. Negrín
    Las Palmas de Gran Canaria, Las Palmas 35010, Spain
    Recruiting
    • David Aguiar, MD · Contact
    • David Aguiar · Principal investigator
  • Hospital Universitario Severo Ochoa
    Leganés, Madrid 28911, Spain
    Recruiting
    • Ana López, MD · Contact
    • Ana López, MD · Principal investigator
  • Hospital Clínico San Carlos
    Madrid, Madrid 28040, Spain
    Recruiting
    • Carlos Aguado, MD · Contact
    • Carlos Aguado, MD · Principal investigator
  • Hospital Universitario Fundación Jiménez Díaz
    Madrid, Madrid 28040, Spain
    Recruiting
    • Manuel Dómine, MD · Contact
    • Manuel Dómine, MD · Principal investigator
  • Hospital Puerta de Hierro
    Madrid, Madrid 28222, Spain
    Recruiting
    • Virginia Calvo, MD · Contact
    • Virginia Calvo, MD · Principal investigator
  • Hospital Universitario Son Espases
    Palma de Mallorca, Mallorca 07120, Spain
    Recruiting
    • Raquel Marsé · Contact
    • Raquel Marsé, MD · Principal investigator
  • Hospital Universitario Regional de Málaga
    Málaga, Málaga 29010, Spain
    Recruiting
    • Vanesa Gutiérrez, MD · Contact
    • Vanesa Gutiérrez, MD · Principal investigator
  • Hospital Universitari Son Llatzer
    Palma de Mallorca, Palma de Mallorca 07198, Spain
    Recruiting
    • Juan Coves Sarto, MD · Contact
    • Juan Coves Sarto, MD · Principal investigator
  • Hospital Universitario Salamanca
    Salamanca, Salamanca 37007, Spain
    Recruiting
    • Alejandro Olivares Hernández, MD · Contact
    • Alejandro Olivares Hernández, MD · Principal investigator
  • Hospital General de Valencia
    Valencia, Valencia 46014, Spain
    Recruiting
    • Paula Espinosa, MD · Contact
    • Paula Espinosa, MD · Principal investigator
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Dec 2031, 77 months after the start.

Of 732 non-industry phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 84. This study's planned 77 months is above that.

Counting every sponsor, half of 1,049 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2025
First posted
Apr 8, 2025
StartActual
Jul 29, 2025
Primary completionEst.
Dec 30, 2031
CompletionEst.
Dec 30, 2031
Last update
Nov 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06917573
Lead sponsor
Fundación GECP
Responsible party
Sponsor
First posted
Apr 8, 2025
Start date
Jul 29, 2025
Primary completion
Dec 30, 2031 (estimated)
Completion
Dec 30, 2031 (estimated)
Last update
Nov 19, 2025

Study contacts

Eva Pereira
Contact
secretaria@gecp.org
+34934302006
Mariano Provencio, MD
study chair · Fundación GECP President

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cemiplimab

Start the discussion